CeriBell (NASDAQ:CBLL) Director Rebecca Robertson Sells 827 Shares

CeriBell, Inc. (NASDAQ:CBLL) Director Rebecca Robertson sold 827 shares of CeriBell stock in a transaction dated Tuesday, March 3rd. The shares were sold at an average price of $17.80, for a total value of $14,720.60. Following the transaction, the director directly owned 18,749 shares in the company, valued at approximately $333,732.20. The trade was a 4.22% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

CeriBell Stock Performance

CeriBell stock traded up $0.02 during midday trading on Thursday, hitting $17.79. The stock had a trading volume of 165,540 shares, compared to its average volume of 345,835. CeriBell, Inc. has a 52-week low of $10.01 and a 52-week high of $24.33. The company has a market capitalization of $669.63 million, a PE ratio of -12.10 and a beta of 1.12. The firm’s fifty day moving average is $20.91 and its two-hundred day moving average is $16.41. The company has a current ratio of 9.73, a quick ratio of 9.35 and a debt-to-equity ratio of 0.13.

CeriBell (NASDAQ:CBLL) last posted its quarterly earnings results on Tuesday, February 24th. The company reported ($0.36) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.07. The business had revenue of $24.78 million during the quarter, compared to analyst estimates of $23.95 million. CeriBell had a negative net margin of 59.97% and a negative return on equity of 31.77%. On average, research analysts forecast that CeriBell, Inc. will post -2.46 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on CBLL shares. BTIG Research reaffirmed a “buy” rating and set a $30.00 target price on shares of CeriBell in a research note on Wednesday, January 28th. JPMorgan Chase & Co. cut their price target on CeriBell from $21.00 to $17.00 and set an “overweight” rating for the company in a report on Wednesday, November 5th. Canaccord Genuity Group upped their price objective on CeriBell from $29.00 to $30.00 and gave the stock a “buy” rating in a report on Wednesday, December 17th. Finally, TD Cowen reaffirmed a “buy” rating on shares of CeriBell in a research note on Tuesday, December 9th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $24.67.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of CBLL. Vanguard Group Inc. increased its holdings in CeriBell by 11.1% in the 3rd quarter. Vanguard Group Inc. now owns 1,473,856 shares of the company’s stock worth $16,935,000 after buying an additional 147,013 shares during the period. Yu Fan raised its stake in shares of CeriBell by 10.7% during the 2nd quarter. Yu Fan now owns 1,353,166 shares of the company’s stock valued at $25,345,000 after buying an additional 130,964 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of CeriBell by 1,945.9% in the 4th quarter. Bank of New York Mellon Corp now owns 1,221,927 shares of the company’s stock valued at $26,797,000 after buying an additional 1,162,200 shares during the period. KCM Capital Inc purchased a new stake in shares of CeriBell in the fourth quarter worth about $21,930,000. Finally, Novo Holdings A S grew its holdings in CeriBell by 2.3% during the second quarter. Novo Holdings A S now owns 900,000 shares of the company’s stock worth $16,857,000 after acquiring an additional 20,000 shares during the period.

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.